Edgewise Therapeutics, Inc.
US ˙ NasdaqGS ˙ US28036F1057

SecurityEWTX / Edgewise Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership372,738 shares
Latest Disclosed Value $ 9,249,495
Barclays Plc reports 58.85% increase in ownership of EWTX / Edgewise Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 372,738 shares of Edgewise Therapeutics, Inc. (US:EWTX) valued at $9,249,493 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 234,650 shares of Edgewise Therapeutics, Inc.. This represents a change in shares of 58.85% during the quarter. The current value of the position is $13,496,843 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 372,738 138,088 58.85 9,249 143.01 0.0022
2026-03-31 2025-09-30 13F/A-3 EDGEWISE THERAPEUTICS COM 28036F105 234,650 -46,600 -16.57 3,806 3.23 0.0008
2026-03-19 2025-09-30 13F/A-2 EDGEWISE THERAPEUTICS COM 28036F105 119,350 -161,900 3,185 0.0008
2025-11-12 2025-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 234,650 -46,600 3,806 0.0008
2026-02-27 2025-06-30 13F/A-2 EDGEWISE THERAPEUTICS COM 28036F105 281,250 172,688 159.07 3,687 54.40 0.0008
2025-08-14 2025-06-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 281,250 172,688 4 0.0008
2025-08-13 2025-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 281,250 172,688 4 0.0003
2026-03-17 2025-03-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 108,562 -25,095 -18.78 2,388 -33.07 0.0007
2025-05-15 2025-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 108,562 -25,095 2 0.0007
2026-03-19 2024-12-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 133,657 14,307 11.99 3,569 12.03 0.0010
2025-02-13 2024-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 133,657 14,307 4 0.0010
2026-03-31 2024-09-30 13F/A-2 EDGEWISE THERAPEUTICS COM 28036F105 119,350 88,826 291.00 3,185 480.15 0.0008
2024-11-19 2024-09-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 119,350 88,826 3 0.0008
2024-11-15 2024-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 119,350 88,826 3 0.0003
2026-03-23 2024-06-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 30,524 -56,720 -65.01 550 -65.49 0.0002
2024-08-14 2024-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 30,524 -56,720 1 0.0002
2026-03-24 2024-03-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 87,244 -691,672 -88.80 1,591 -81.33 0.0006
2024-05-15 2024-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 87,244 -691,672 2 0.0006
2026-03-25 2023-12-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 778,916 760,637 4,161.26 8,521 8,093.27 0.0031
2024-02-15 2023-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 778,916 760,637 9 0.0031
2026-03-26 2023-09-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 18,279 1,003 5.81 105 -21.80 0.0001
2023-11-07 2023-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 18,279 1,003 0 0.0001
2026-03-30 2023-06-30 13F/A-2 EDGEWISE THERAPEUTICS COM 28036F105 17,276 -10,740 -38.34 134 -28.49 0.0001
2023-09-20 2023-06-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 17,276 -10,740 0 0.0001
2023-08-03 2023-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 17,276 -10,740 0 0.0001
2026-03-30 2023-03-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 28,016 9,783 53.66 187 14.11 0.0001
2023-05-04 2023-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 28,016 9,783 0 0.0001
2026-03-30 2022-12-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 18,233 8,918 95.74 163 79.12 0.0001
2023-02-13 2022-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 18,233 8,918 0 0.0001
2022-11-03 2022-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 9,315 -209,993 -95.75 91 -94.79 0.0001
2022-08-12 2022-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 219,308 -652 -0.30 1,746 -18.18 0.0011
2022-05-16 2022-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 219,960 219,960 2,134 0.0017
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.